The global next generation sequencing (NGS) market is witnessing significant growth, driven by the increasing demand for personalized medicine, advancements in genomics, and the rising prevalence of genetic disorders. The market is bolstered by technological innovations that make NGS more accessible and affordable, with applications spanning from diagnostics to drug development. Additionally, the growing adoption of NGS in oncology for cancer genomics and targeted therapies is further fueling market expansion. Key players are also focusing on developing advanced, high-throughput sequencers that can provide faster, more accurate results at lower costs. Furthermore, the rise in government investments, along with collaborations between academic institutions and biotechnology firms, is helping to accelerate research and development in the field. Despite challenges related to data complexity and the high cost of sequencing, the NGS market continues to expand rapidly, positioning it as a key player in the evolution of molecular diagnostics and healthcare solutions.
Global Next Generation Sequencing (NGS) Market is valued at USD 13.88 billion in 2023 and is expected to reach USD 40.78 billion by 2031, with a growing CAGR of 15.1% during the forecast period 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/reports/global-next-generation-sequencing-ngs-market
Below are the Top Next Generation Sequencing (NGS) Companies with a Significant Market Share:
|
Rank |
Company |
Overview |
Product Portfolio |
Sales Geographical Coverage |
Developments |
|
1. |
Illumina, Inc. |
Illumina, Inc. is the undisputed leader in the global next-generation sequencing (NGS) market, revolutionizing genomic research and diagnostics. The company designs and manufactures sequencing systems and reagents that enable high-throughput DNA sequencing, making it more accessible and affordable. Illumina's sequencing technologies are widely used in various applications, including genomics research, clinical diagnostics, oncology, and agricultural studies. The company's NovaSeq, MiSeq, and NextSeq platforms are known for their high accuracy, speed, and scalability, making Illumina a preferred choice for researchers and clinical labs globally. Illumina continues to push the boundaries of genomic science by advancing its technology, improving data quality, and expanding its offerings for clinical and personalized medicine. |
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe |
In August 2021, Illumin Inc. announced that it has acquired GRAIL to accelerate patient access to multi cancer early detection test and gene sequencing procedures. This has helped the company to increase its product portfolio. |
|
2. |
Thermo Fisher Scientific Inc. |
Thermo Fisher Scientific Inc. is a leading player in the life sciences, analytical instruments, and healthcare sectors. In the NGS market, Thermo Fisher provides a comprehensive suite of sequencing instruments, reagents, and bioinformatics solutions. The company’s Ion Proton, Ion GeneStudio, and Applied Biosystems sequencers cater to both research and clinical applications. Thermo Fisher's next-gen sequencing platforms are known for their accuracy, flexibility, and ease of use, with applications spanning from basic genomic research to targeted oncology sequencing. Thermo Fisher also offers cloud-based data storage and analysis services, making it a key player in advancing the accessibility and capabilities of NGS technologies. |
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe |
In October 2021, ThermoFisher Scientific Inc. announced that it has launched Applied Biosystem QuantSudio Absolute Q-Digital PCR System, which is a designed to provide highly accurate results in genetic analysis. The digital PCR is already in use for monitoring cancer driven mutations in liquid biopsy. This has helped he company to increase its product portfolio. |
|
3. |
QIAGEN |
QIAGEN is a global provider of molecular diagnostics, life sciences research tools, and sample preparation technologies. In the NGS market, QIAGEN offers a range of solutions for sample extraction, library preparation, and sequencing. Its GeneReader NGS platform is a prominent product, known for its simplicity and integration, enabling researchers to perform genomic analyses efficiently. Additionally, QIAGEN offers a wide portfolio of reagents and bioinformatics tools for NGS, which are used in applications ranging from oncology to infectious disease research. The company’s focus on precision medicine and personalized diagnostics continues to drive growth in the NGS space. |
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe |
In February 2024, QIAGEN announced that it has been recognized for its sustainability efforts by My Green Lab, a non-profit organization focused on promoting sustainability in scientific research. This will enhance QIAGEN's reputation for sustainability, potentially attracting environmentally conscious customers and partners. |
|
4. |
Merck KGaA |
Merck KGaA, Darmstadt, is a global science and technology company that provides products and services across healthcare, life sciences, and performance materials. In the NGS market, Merck offers a variety of consumables and instrumentation, particularly through its Sigma-Aldrich and EMD Millipore brands. Merck KGaA’s Microsatellites and KAPA Biosystems NGS products are widely used in genomic research, enabling high-quality sequencing data with greater flexibility and scalability. Merck is also focused on developing solutions for data analysis and interpretation, positioning itself as a key enabler in the next-gen sequencing revolution, particularly in oncology and rare disease diagnostics. |
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe |
In April 2024, Merck KGaA has introduced the industry's first all-in-one, validated genetic stability assay. The Aptegra CHO genetic stability assay uses whole genome sequencing and bioinformatics to speed up biosafety testing for clients, facilitating their transition to commercial production. This innovation will help Merck KGaA streamline biosafety testing for clients, enabling faster transitions to commercial production and enhancing their competitiveness in the market. |
|
5. |
Charles River Laboratories |
Charles River Laboratories is a leading provider of comprehensive services to the pharmaceutical and biotechnology industries, with expertise in preclinical and clinical research. In the NGS market, Charles River offers contract research services that incorporate NGS technology to assist with drug discovery, biomarker identification, and preclinical trials. The company’s NGS services are used to perform gene expression analysis, sequencing of exomes, and whole-genome sequencing, among other applications. Charles River Laboratories is helping to drive the integration of NGS into drug development processes, particularly in the areas of oncology, immunotherapy, and personalized medicine. |
Contamination Testing
Accugenix |
North America, South America, Middle East and Africa, Asia-Pacific, and Europe |
In May 2023, Charles River Laboratories has introduced Accugenix Next Generation Sequencing for Bacterial Identification and Fungal Identification (Accugenix NGS). This technology sequences millions of individual DNA fragments from a sample, offering pharmaceutical and personal care manufacturers crucial microbial control information. The new technology enhances the company's services, offering pharmaceutical and personal care manufacturers advanced microbial control solutions that improve product quality and regulatory compliance. |
Conclusion
The global next generation sequencing (NGS) market is experiencing robust growth, driven by advancements in genomics, personalized medicine, and the increasing application of NGS in various medical fields, particularly oncology. Technological innovations are making sequencing more efficient, accessible, and cost-effective, enabling broader adoption across healthcare and research sectors. With continued investment in R&D, partnerships between academia and industry, and expanding use in diagnostics and drug development, the NGS market is poised for further expansion. However, overcoming challenges such as data complexity and sequencing costs will be key to maintaining this momentum and achieving widespread clinical integration. Overall, NGS is emerging as a transformative force in molecular diagnostics, offering significant potential for personalized healthcare solutions.
